Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Psychiatry. Feb 19, 2022; 12(2): 298-307
Published online Feb 19, 2022. doi: 10.5498/wjp.v12.i2.298
Table 1 Demographic information for the two study cohorts
Demographic
Category
Total
Medication group
Comparison group
Number of patients1480587893
Age (mean ± SD)82.6 ± 8.181.7 ± 8.483.3 ± 7.9
GenderMale714 (48.2%)294 (50.1%)420 (47.0%)
Female766 (51.8%)293 (49.9%)473 (53.0%)
Other/NA000
EthnicityWhite-British1033 (69.8%)451 (76.8%)582 (65.2%)
White-Irish5 (< 1%)4 (< 1%)1 (< 1%)
White-Any other17 (1.1%)6 (1.0%)11 (1.2%)
Mixed-White and Asian1 (< 1%)1 (< 1%)0 (< 1%)
Asian-Indian6 (< 1%)2 (< 1%)4 (< 1%)
Asian-Bangladeshi1 (< 1%)0 (< 1%)1 (< 1%)
Asian-Any other10 (< 1%)5 (< 1%)5 (< 1%)
Black-Caribbean2 (< 1%)1 (< 1%)1 (< 1%)
Black-African2 (< 1%)1 (< 1%)1 (< 1%)
Any other ethnic group2 (< 1%)2 (< 1%)0 (< 1%)
Not stated/NA401 (27.1%)114 (19.4%)287 (32.1%)
MMSENumber of patients with MMSE608 (41.1%)226 (38.5%)382 (42.8%)
Number of patients without MMSE876 (58.9%)361 (61.5%)511 (57.2%)
MMSE score20-30369 (60.7%)101 (44.7%)268 (70.2%)
10-19199 (23.7%)98 (43.4%)101 (26.4%)
< 1040 (6.56%)27 (11.9%)13 (3.4%)
Table 2 Results of the cox proportional hazard model, with survival since diagnosis as the duration variable
Covariate
Total
Alive
Dead
Hazard ratio
P value
Medications
Olanzapine15533 (21.3%)122 (78.7%)1.32a (1.08-1.60)< 0.01
Quetiapine14429 (20.1%)115 (79.9%)1.09 (0.90-1.34)0.38
Risperidone45082 (18.2%)368 (81.8%)1.35b (1.18-1.54)< 0.001
Gender
Male714165 (23.1%)549 (76.9%)Baseline
Female766218 (28.5%)548 (71.5%)0.73b (0.64-0.82)< 0.001
Ethnicity
White-British1033275 (26.6%)758 (73.4%)0.82a (0.72-0.94)< 0.01
White-Irish52 (40.0%)3 (60.0%)0.51 (0.16-1.62)0.26
White-Any other176 (35.3%)11 (64.7%)0.62 (0.34-1.13)0.12
Mixed-White and Asian-----
Asian-Indian61 (16.7%)5 (83.3%)1.49 (0.61-3.63)0.38
Asian-Bangladeshi-----
Asian-Any other106 (60.0%)4 (40.0%)0.17a (0.05-0.53)< 0.01
Black-Caribbean-----
Black-African-----
Any other ethnic group-----
MMSE score
20-30369123 (33.3%)246 (66.7%)0.72b (0.62-0.83)< 0.001
10-1919945 (22.6%)154 (77.4%)0.87 (0.73-1.04)0.12
< 104011 (27.5%)29 (72.5%)0.81 (0.56-1.19)0.28